Medical

King's College London will be the site of Phase 2 trials of Lightlake Therapeutics's opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland to demonstrate the effectiveness of its naloxone nasal spray for the treatment of binge eating disorder in overweight and obese … [Read more...] about Lightlake announces Phase 2 trial of nasal spray for bulimia nervosa

Novartis Pharmaceuticals Canada has announced that the Québec provincial government will now provide reimbursement for the TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.The company cites data from Cystic Fibrosis Canada that show about 1,200 cystic fibrosis patients residing in Québec. TOBI Podhaler … [Read more...] about Quebec is first Canadian province to offer formulary access to TOBI Podhaler

Teva Respiratory has announced that it will provide assistance to patients affected by the impending phase out of the OTC Primatene Mist epinephrine inhaler. In addition to providing educational resources, the company says that it will offer financial assistance programs and samples of its ProAir HFA albuterol and QVar HFA beclamethasone metered dose inhalers. Teva … [Read more...] about Teva offering assistance to Primatene Mist users

A Phase 1 clinical trial of a novel dry powder intranasal vaccine for prevention of the H5N1 influenza strain demonstrated that the product was well tolerated, and no serious adverse events occurred, according to developer Nanotherapeutics. the GelVac nasal dry powder H5N1 vaccine is delivered by a disposable single-use positive pressure intranasal inhaler that uses … [Read more...] about No safety problems for Nanotherapeutics’ nasal dry powder vaccine in Phase 1 trial

The International Primary Care Respiratory Group (IPCRG) has launched a petition in support of its Fresh Air Uganda study in response to what it says is a growing threat in the region, with COPD expected to surpass HIV/AIDs as the third-leading cause of death in Africa by 2025. The epidemiological study in rural Uganda will involve 600 people over the age of 30, … [Read more...] about Effort to study COPD prevalence in Sub-Saharan African launched

Massachusetts biotech company Pulmatrix presented data from two studies of its Pulmatrix presents data from preclinical studies of its lead product, PUR118, an inhaled cationic airway lining modulator (iCALM) for the treatment of respiratory diseases in oral and poster sessions at the 2011 European Respiratory Society (ERS) conference. The data show that PUR118 … [Read more...] about Pulmatrix presents data from preclinical studies of its inhaled calcium salts

Almirall has presented a number of posters at the 2011 Annual Congress of the European Respiratory Society (ERS), including, for the first time, full data from the six-month Phase 3 ATTAIN study of its aclidinium bromide dry powder inhaler for the treatment of moderate-to-severe COPD. The data show that twice-daily doses of either 200 μg or 400 μg of aclidinium … [Read more...] about Amirall presents full data for Phase 3 ATTAIN study of aclidinium bromide at ERS

MicroDose Therapeutx has initiated a Phase 1 clinical trial of MDT-637, an inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV) that is delivered using the company's novel dry powder nebulizer. MicroDose is developing MDT-637 in partnership with Gilead Sciences and will develop the product through Phase 2a trials. … [Read more...] about MicroDose begins Phase 1 trial of novel dry powder nebulized treatment for RSV

Two posters presented by Pearl Therapeutics at the 2011 European Respiratory Society meeting show additional data from a Phase 2b study demonstrating that Pearl's glycopyrrolate (GP)/fomoterol fumarate (FF) fixed combination metered dose inhaler and its PT001 GP monotherapy MDI both provide greater inspiratory capacity than Spiriva Handihaler tiotropium dry powder … [Read more...] about Pearl Therapeutics announces positive Phase 2b results for PT003 inhaler